antibiot antibacteri type antimicrobi use treatment prevent bacteri infect may either kill inhibit growth bacteria sever antibiot also effect fungi protozoan toxic human anim even given therapeut dosag antibiot effect virus common cold influenza may harm taken inappropri
alexand fleme identifi penicillin first chemic compound antibiot properti fleme work cultur diseasecaus bacteria notic spore littl green mold one cultur plate observ presenc mold kill prevent growth bacteria
antibiot revolution medicin th centuri togeth vaccin led near erad diseas tuberculosi develop world effect easi access led overus especi livestock rais prompt bacteria develop resist led widespread problem antimicrobi antibiot resist much prompt world health organ classifi antimicrobi resist serious threat longer predict futur happen right everi region world potenti affect anyon age countri
era antibacteri chemotherapi began discoveri arsphenamin first synthes alfr bertheim paul ehrlich use treat syphili first system activ antibacteri drug prontosil discov gerhard domagk award nobel prize class antibiot use today first discov prior mid
sometim term antibiot use refer substanc use microb synonym antimicrobi lead widespread incorrect belief antibiot use virus sourc distinguish antibacteri antibiot antibacteri use soap cleaner etc medicin articl treat term synonym accord widespread definit antibiot substanc use bacteria
medic use
treatment
bacteri infect
protozoan infect eg metronidazol bactrim effect sever parasit
immunomodul eg tetracyclin effect periodont inflamm dapson effect autoimmun diseas oral mucous membran pemphigoid
nonop resourc patient noncompl acut append treatment antibiot report work almost case remiss
prevent infect
surgic wound
dental antibiot prophylaxi
condit neutropenia eg cancerrel
pharmacodynam
success outcom antimicrobi therapi antibacteri compound depend sever factor includ host defens mechan locat infect pharmacokinet pharmacodynam properti antibacteri bactericid activ antibacteri may depend bacteri growth phase often requir ongo metabol activ divis bacteri cell find base laboratori studi clinic set also shown elimin bacteri infect sinc activ antibacteri depend frequent concentr vitro character antibacteri activ common includ determin minimum inhibitori concentr minimum bactericid concentr antibacteri predict clinic outcom antimicrobi activ antibacteri usual combin pharmacokinet profil sever pharmacolog paramet use marker drug efficaci
class
antibacteri antibiot common classifi base mechan action chemic structur spectrum activ target bacteri function growth process target bacteri cell wall penicillin cephalosporin cell membran polymyxin interfer essenti bacteri enzym rifamycin lipiarmycin quinolon sulfonamid bactericid activ target protein synthesi macrolid lincosamid tetracyclin usual bacteriostat except bactericid aminoglycosid categor base target specif narrowspectrum antibacteri antibiot target specif type bacteria gramneg gramposit bacteria wherea broadspectrum antibiot affect wide rang bacteria follow year hiatus discov new class antibacteri compound four new class antibacteri antibiot brought clinic use late earli cyclic lipopeptid daptomycin glycylcyclin tigecyclin oxazolidinon linezolid lipiarmycin fidaxomicin
product
advanc medicin chemistri modern antibacteri semisynthet modif various natur compound includ exampl betalactam antibiot includ penicillin produc fungi genus penicillium cephalosporin carbapenem compound still isol live organ aminoglycosid wherea antibacterialsfor exampl sulfonamid quinolon oxazolidinonesar produc sole chemic synthesi accord mani antibacteri compound classifi basi chemicalbiosynthet origin natur semisynthet synthet anoth classif system base biolog activ classif antibacteri divid two broad group accord biolog effect microorgan bactericid agent kill bacteria bacteriostat agent slow stall bacteri growth mani antibacteri compound relat small molecul molecular weight less atom mass unit
sinc first pioneer effort florey chain import antibiot includ antibacteri medicin led intens research produc antibacteri larg scale follow screen antibacteri wide rang bacteria product activ compound carri use ferment usual strong aerob condit
administr
oral antibiot taken mouth wherea intraven administr may use serious case deepseat system infect antibiot may also sometim administ topic eye drop ointment
topic antibiot
erythromycin
clindamycin
gentamycin
tetracyclin
meclocyclin
sodium sulfacetamid
topic medic act comedolyt well antibiot
benzoyl peroxid
azela acid
sideeffect
antibiot screen negat effect human mammal approv clinic use usual consid safe well toler howev antibiot associ rang advers side effect sideeffect rang mild serious depend antibiot use microbi organ target individu patient safeti profil newer drug often well establish long histori use advers effect rang fever nausea major allerg reaction includ photodermat anaphylaxi common sideeffect includ diarrhea result disrupt speci composit intestin flora result exampl overgrowth pathogen bacteria clostridium difficil antibacteri also affect vagin flora may lead overgrowth yeast speci genus candida vulvovagin area addit sideeffect result interact drug elev risk tendon damag administr quinolon antibiot system corticosteroid scientist hypothes indiscrimin use antibiot alter host microbiota associ chronic diseas
drugdrug interact
birth control pill
major studi indic antibiot interfer contracept pill clinic studi suggest failur rate contracept pill caus antibiot low case antibacteri suggest affect effici birth control pill broadspectrum antibacteri rifampicin case may due increas activ hepat liver enzym caus increas breakdown pill activ ingredi effect intestin flora might result reduc absorpt estrogen colon also suggest suggest inconclus controversi clinician recommend extra contracept measur appli therapi use antibacteri suspect interact oral contracept
alcohol
interact alcohol certain antibiot may occur may caus sideeffect decreas effect antibiot therapi
sensibl avoid drink alcohol take medic howev unlik drink alcohol moder caus problem take common antibiot howev specif type antibiot alcohol avoid complet serious sideeffect
therefor potenti risk sideeffect effect depend type antibiot administ despit lack categor counterind belief alcohol antibiot never mix widespread
antibiot metronidazol tinidazol cephamandol latamoxef cefoperazon cefmenoxim furazolidon caus disulfiramlik chemic reaction alcohol inhibit breakdown acetaldehyd dehydrogenas may result vomit nausea short breath
effect alcohol antibiot activ includ alter activ liver enzym break antibiot compound addit serum level doxycyclin erythromycin succin two bacteriostat antibiot see may reduc alcohol consumpt result reduc efficaci diminish pharmacotherapeut effect
resist
emerg resist bacteria antibiot common phenomenon emerg resist often reflect evolutionari process take place antibiot therapi antibiot treatment may select bacteri strain physiolog genet enhanc capac surviv high dose antibiot certain condit may result preferenti growth resist bacteria growth suscept bacteria inhibit drug exampl antibacteri select strain previous acquir antibacterialresist gene demonstr luriadelbrck experi antibiot penicillin erythromycin use high efficaci mani bacteri speci strain becom less effect due increas resist mani bacteri strain
resist may take form biodegred pharmaceut sulfamethazinedegrad soil bacteria introduc sulfamethazin medic pig fece surviv bacteria often result inherit resist growth resist antibacteri also occur horizont gene transfer horizont transfer like happen locat frequent antibiot use
antibacteri resist may impos biolog cost therebi reduc fit resist strain limit spread antibacterialresist bacteria exampl absenc antibacteri compound addit mutat howev may compens fit cost aid surviv bacteria
paleontolog data show antibiot antibiot resist ancient compound mechan use antibiot target mutat negat impact bacteri reproduct viabil
sever molecular mechan antibacteri resist exist intrins antibacteri resist may part genet makeup bacteri strain exampl antibiot target may absent bacteri genom acquir resist result mutat bacteri chromosom acquisit extrachromosom dna antibacterialproduc bacteria evolv resist mechan shown similar may transfer antibacterialresist strain spread antibacteri resist often occur vertic transmiss mutat growth genet recombin dna horizont genet exchang instanc antibacteri resist gene exchang differ bacteri strain speci via plasmid carri resist gene plasmid carri sever differ resist gene confer resist multipl antibacteri crossresist sever antibacteri may also occur resist mechan encod singl gene convey resist one antibacteri compound
antibacterialresist strain speci sometim refer superbug contribut emerg diseas well control exampl emerg bacteri strain caus tuberculosi tb resist previous effect antibacteri treatment pose mani therapeut challeng everi year near half million new case multidrugresist tuberculosi mdrtb estim occur worldwid exampl ndm newli identifi enzym convey bacteri resist broad rang betalactam antibacteri unit kingdom health protect agenc state isol ndm enzym resist standard intraven antibiot treatment sever infect
misus
per icu book first rule antibiot tri use second rule tri use mani
inappropri antibiot treatment overus antibiot contribut emerg antibioticresist bacteria self prescript antibiot exampl misus mani antibiot frequent prescrib treat symptom diseas respond antibiot like resolv without treatment also incorrect suboptim antibiot prescrib certain bacteri infect overus antibiot like penicillin erythromycin associ emerg antibiot resist sinc widespread usag antibiot hospit also associ increas bacteri strain speci longer respond treatment common antibiot
common form antibiot misus includ excess use prophylact antibiot travel failur medic profession prescrib correct dosag antibiot basi patient weight histori prior use form misus includ failur take entir prescrib cours antibiot incorrect dosag administr failur rest suffici recoveri inappropri antibiot treatment exampl prescript treat viral infect common cold one studi respiratori tract infect found physician like prescrib antibiot patient appear expect multifactori intervent aim physician patient reduc inappropri prescript antibiot
sever organ concern antimicrobi resist lobbi elimin unnecessari use antibiot issu misus overus antibiot address format us interag task forc antimicrobi resist task forc aim activ address antimicrobi resist coordin us center diseas control prevent food drug administr fda nation institut health nih well us agenc ngo campaign group keep antibiot work franc antibiot automat govern campaign start led mark reduct unnecessari antibiot prescript especi children
emerg antibiot resist prompt restrict use uk swann report eu ban use antibiot growthpromot agent sinc moreov sever organ eg american societi microbiolog asm american public health associ apha american medic associ ama call restrict antibiot use food anim product end nontherapeut use howev common delay regulatori legisl action limit use antibiot attribut part resist regul industri use sell antibiot time requir research test causal link use resist two feder bill hr aim phase nontherapeut use antibiot us food anim propos pass bill endors public health medic organ includ american holist nurs associ american medic associ american public health associ apha
extens use antibiot anim husbandri unit state question emerg antibioticresist bacteri strain due use antibiot livestock rais us food drug administr fda march unit state district court southern district new york rule action brought natur resourc defens council other order fda revok approv use antibiot livestock violat fda regul
altern
increas bacteri strain resist convent antibacteri therapi prompt develop bacteri diseas treatment strategi altern convent antibacteri
resistancemodifi agent
one strategi address bacteri drug resist discoveri applic compound modifi resist common antibacteri exampl resistancemodifi agent may inhibit multidrug resist mechan drug efflux cell thus increas suscept bacteria antibacteri target includ
efflux inhibitor pheargnaphthylamid
betalactamas inhibitor clavulan acid sulbactam
metabol stimuli sugar help erad certain type antibiotictoler bacteria keep metabol activ
vaccin
vaccin reli immun modul augment vaccin either excit reinforc immun compet host ward infect lead activ macrophag product antibodi inflamm classic immun reaction antibacteri vaccin respons drastic reduct global bacteri diseas vaccin made attenu whole cell lysat replac larg less reactogen cellfre vaccin consist purifi compon includ capsular polysaccharid conjug protein carrier well inactiv toxin toxoid protein
phage therapi
phage therapi anoth option look treat resist strain bacteria way research infect pathogen bacteria virus specif bacteriophag bacteriophag also known simpli phage precis bacteri virus infect bacteria disrupt pathogen bacterium lytic cycl disrupt lytic cycl bacterium phage destroy metabol eventu result cell death phage insert dna bacterium allow dna transcrib dna transcrib cell proceed make new phage soon readi releas cell lyse one worri use phage fight pathogen phage infect good bacteria bacteria import everyday function human be howev studi proven phage specif target bacteria make research confid bacteriophag therapi definit rout defeat antibiot resist bacteria
supplement
overthecount antioxid supplement contain polyphenol grape seed extract demonstr vitro antibacteri properti
status new antibiot develop
polici report releas infecti diseas societi america idsa april idsa express grave concern weak pipelin antibiot combat grow abil bacteria especi gramneg bacilli gnb develop resist antibiot sinc new antibiot approv unit state number new antibiot annual approv market continu declin report could identifi seven antibiot current phase phase clinic trial treat gnb includ e coli salmonella shigella enterobacteriacea bacteria drug address entir spectrum resist develop bacteria seven new antibiot combin exist antibiot includ
ceftolozanetazobactam cxa cxatazobactam antipseudomon cephalosporinlactamas inhibitor combin cell wall synthesi inhibitor fda approv
ceftazidimeavibactam ceftazidimenxl antipseudomon cephalosporinlactamas inhibitor combin cell wall synthesi inhibitor phase
ceftarolineavibactam cptavibactam ceftarolinenxl antimrsa cephalosporin lactamas inhibitor combin cell wall synthesi inhibitor
imipenemmk carbapenem lactamas inhibitor combin cell wall synthesi inhibitor phase
plazomicin achn aminoglycosid protein synthesi inhibitor phase
eravacyclin tp synthet tetracyclin deriv protein synthesi inhibitor target ribosom develop tetraphas phase trial complet
brilacidin pmx peptid defens protein mimet cell membran disrupt phase
mani new antibiot still come research streptomyc includ new pharmaceut abl treat mrsa infect resist commonlyus medic invest sector research made profound impact uk economi human health streptomyc research support bbsrc john inn centr univers uk result creation number spinout compani one novacta biosystem design typeb lantibioticbas compound nvb phase treat clostridium difficil infect
idsa prognosi sustain rd infrastructur antibiot develop depend upon clarif fda regulatori clinic trial guidanc would facilit speedi approv new drug appropri econom incent pharmaceut compani invest endeavor decemb antibiot develop advanc patient treatment adapt act introduc us congress adapt act aim fast track drug develop order combat grow public health threat superbug act fda approv antibiot antifung need lifethreaten infect base data smaller clinic trial cdc reinforc monitor use antibiot treat serious lifethreaten infect emerg resist make data public avail fda antibiot label process suscept test interpret criteria microbi organ breakpoint also streamlin allow uptod cuttingedg data avail healthcar profession new act congress urg sever parti aid develop new drug via bill adapt allan coukel director drug medic devic pew charit trust testifi hous committe statement publish reuter allow drug develop reli smaller dataset clarifi fdas author toler higher level uncertainti drug make riskbenefit calcul adapt would make clinic trial feasibl
antibiot antagon
chloramphenicol tetracyclin antagonist penicillin aminoglycosid mean combin effect two antibiot separ group less singl antibiot howev vari depend speci bacteria
histori
earli th centuri treatment infect base primarili medicin folklor mixtur antimicrobi properti use treatment infect describ year ago mani ancient cultur includ ancient egyptian ancient greek use special select mold plant materi extract treat infect recent observ made laboratori antibiosi microorgan led discoveri natur antibacteri produc microorgan loui pasteur observ could interven antagon observ bacteria would offer perhap greatest hope therapeut term antibiosi mean life introduc french bacteriologist jean paul vuillemin descript name phenomenon exhibit earli antibacteri drug antibiosi first describ bacteria loui pasteur robert koch observ airborn bacillus could inhibit growth bacillus anthraci drug later renam antibiot selman waksman american microbiologist synthet antibiot chemotherapi scienc develop antibacteri began germani paul ehrlich late ehrlich note certain dye would color human anim bacteri cell wherea other propos idea might possibl creat chemic would act select drug would bind kill bacteria without harm human host screen hundr dye various organ discov medicin use drug synthet antibacteri salvarsan call arsphenamin
effect type mold infect notic mani time cours histori see histori penicillin alexand fleme notic effect petri dish number diseasecaus bacteria kill fungus genus penicillium fleme postul effect mediat antibacteri compound name penicillin antibacteri properti could exploit chemotherapi initi character biolog properti attempt use crude prepar treat infect unabl pursu develop without aid train chemist
first sulfonamid first commerci avail antibacteri prontosil develop research team led gerhard domagk bayer laboratori ig farben conglomer germani domagk receiv nobel prize medicin effort prontosil relat broad effect gramposit cocci enterobacteria research stimul apac success discoveri develop sulfonamid drug open era antibacteri
coincid start world war ii rene dubo report discoveri first natur deriv antibiot tyrothricin compound gramicidin tyrocidin b brevi one first commerci manufactur antibiot univers effect treat wound ulcer world war ii gramicidin howev could use system toxic tyrocidin also prove toxic system usag research result obtain period share axi alli power war
florey chain succeed purifi first penicillin penicillin g becom wide avail outsid alli militari chemic structur penicillin determin dorothi crowfoot hodgkin purifi penicillin display potent antibacteri activ wide rang bacteria low toxic human furthermor activ inhibit biolog constitu pus unlik synthet sulfonamid discoveri power antibiot unpreced develop penicillin led renew interest search antibiot compound similar efficaci safeti success develop penicillin fleme accident discov could develop therapeut drug ernst chain howard florey share nobel prize medicin fleme florey credit dubo pioneer approach deliber systemat search antibacteri compound led discoveri gramicidin reviv florey research penicillin
etymolog
term antibiot first use selman waksman collabor journal articl describ substanc produc microorgan antagonist growth microorgan high dilut definit exclud substanc kill bacteria produc microorgan gastric juic hydrogen peroxid also exclud synthet antibacteri compound sulfonamid
term antibiot deriv anti bitiko fit life live come bisi way life bio life
term antibacteri deriv greek anti baktrion diminut baktria staff cane first one discov rodshap
see also
antivir
antifung
antiprotozo
antimalari
refer
extern link
antibiot dmoz
